Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
The Cancer Clinic, St. Olav's Hospital, Trondheim, Norway.
Sci Data. 2019 Oct 29;6(1):237. doi: 10.1038/s41597-019-0255-7.
While there is a high interest in drug combinations in cancer therapy, openly accessible datasets for drug combination responses are sparse. Here we present a dataset comprising 171 pairwise combinations of 19 individual drugs targeting signal transduction mechanisms across eight cancer cell lines, where the effect of each drug and drug combination is reported as cell viability assessed by metabolic activity. Drugs are chosen by their capacity to specifically interfere with well-known signal transduction mechanisms. Signalling processes targeted by the drugs include PI3K/AKT, NFkB, JAK/STAT, CTNNB1/TCF, and MAPK pathways. Drug combinations are classified as synergistic based on the Bliss independence synergy metrics. The data identifies combinations that synergistically reduce cancer cell viability and that can be of interest for further pre-clinical investigations.
虽然人们对癌症治疗中的药物组合非常感兴趣，但公开可用的药物组合反应数据集却很少。在这里，我们提供了一个数据集，其中包含 171 对 19 种针对信号转导机制的单个药物的组合，这些药物在八种癌细胞系中的作用是通过代谢活性评估的细胞活力来报告的。这些药物是根据其特异性干扰已知信号转导机制的能力选择的。药物靶向的信号转导过程包括 PI3K/AKT、NFkB、JAK/STAT、CTNNB1/TCF 和 MAPK 途径。根据 Bliss 独立性协同作用度量标准，将药物组合分类为协同作用。这些数据确定了协同降低癌细胞活力的组合，这些组合可能对进一步的临床前研究感兴趣。
Zotero 插件
